Viewing Study NCT05120960


Ignite Creation Date: 2025-12-25 @ 2:03 AM
Ignite Modification Date: 2025-12-26 @ 12:28 AM
Study NCT ID: NCT05120960
Status: WITHDRAWN
Last Update Posted: 2024-04-17
First Post: 2021-11-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module